Orszagos Onkologiai Intezet

Their core work

Hungary's National Institute of Oncology (OOI) is a leading cancer research and treatment center based in Budapest. Their H2020 work focuses on targeted tumor therapy — specifically peptide-drug conjugates and small-molecule drug conjugates that deliver cytotoxic agents directly to cancer cells. They also contribute to European genomics infrastructure, particularly around data standards and personalized medicine frameworks for healthcare systems.

What they specialise in

How they've shifted over time

OOI's early H2020 involvement (2015) centered on peptide-drug conjugates for tumor targeting and translational cancer research coordination. By 2019-2020, their focus broadened in two directions: the drug conjugate work evolved from peptides to small molecules (Magicbullet Reloaded), and they entered the genomics and health data infrastructure space through B1MG. This suggests a shift from purely experimental oncology toward integrating precision medicine and data-driven approaches into their cancer research.

OOI is moving toward precision oncology, combining their drug delivery expertise with genomic data standards — positioning them well for future personalized cancer treatment projects.

How they like to work

OOI operates exclusively as a participant, never as coordinator, which is typical for a specialized clinical research institute contributing domain expertise to larger consortia. With 85 unique partners across 25 countries in just 4 projects, they work within large, pan-European networks rather than small focused teams. This makes them an accessible and experienced consortium partner — accustomed to multi-national collaboration and likely easy to integrate into new projects.

Despite only 4 projects, OOI has built a broad network of 85 partners across 25 countries, reflecting their participation in large pan-European consortia. Their network spans both biomedical research institutions and health data infrastructure organizations.

What sets them apart

OOI is Hungary's primary oncology research center, which gives them access to clinical data, patient cohorts, and treatment infrastructure that university labs typically lack. Their dual track — experimental drug conjugates plus genomic data standardization — is an uncommon combination that bridges wet-lab cancer therapeutics with digital health infrastructure. For consortium builders, they offer both clinical oncology credibility and Central European geographic coverage, a region often underrepresented in large health projects.

Highlights from their portfolio

• Magicbullet Reloaded
  Largest single EC contribution (EUR 229,715), a direct continuation and expansion of the original MAGICBULLET project — showing sustained commitment to targeted drug delivery over nearly a decade.
• B1MG
  Represents a strategic pivot into genomics and health data infrastructure (EOSC, FAIR principles), connecting OOI to the major European personalized medicine initiative Beyond 1 Million Genomes.